A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 19
- Population
- ALL · 50 Years
- Duration
- 2011-07-07 to 2012-04-16
- Intervention
- pazopanib eye drops
- Comparator
- Not reported
- Outcomes measured
- Change From Baseline in Central Retinal Lesion Thickness (CRT) as Measured by Optical Coherence Tomography (OCT) at Day…; Change From Baseline in Best Correct Visual Acuity (BCVA) as Measured by the Number of Letters Determined by Electronic…; Change From Baseline in Central Retinal Lesion Thickness (CRLT) Over Time — Baseline (Week -3 to -1) Up to Follow-up (D…; Change From Baseline in Intraretinal (IR) or Subretinal (SR) Fluid Thickness, Intraretinal Cysts or Serous Retinal Pigm…; Change From Baseline in BCVA Over Time — Baseline (Week -3 to -1) Up to Follow-up (Day 102); Change From Baseline in the Area of Choroidal Neovascular (CNV) Size and CNV Total Lesion Complex Size as Measured by F…; Number of Participants With Change in Charactertsics (Atrophy, Pigment, SR Hemorrhage, IR Hemorrhage, SR Fluid and Fibr…; Number of Participants Who Received Rescue Medication — Up to follow-up (Day 102); Number of Participants With Ocular Adverse Events (AEs), Non-ocular AEs, Serious Ocular AEs and Serious Non-ocular AEs…; Number of Participants With Values of Potential Clinical Concern for Ocular Assessments on General Ophthalmic Examinati…; Number of Participants With Vital Sign Data of Potential Clinical Concern — Up to Follow-up (Day 102); Number of Participants With Clinical Chemistry and Hematology Data of Potential Clinical Concern — Up to Follow-up (Day…; Number of Participants With Abnormal Urinalysis Data by Urine Microscopy and Dipstick Analysis — Up to Follow-up (Day 1…; Summary of Plasma Pazonib Concentration — Up to Week 12
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.